Miach Orthopaedics, a company focused on advancing the treatment of anterior cruciate ligament tears, on Sept. 7 named Patrick McBrayer as president and CEO.
Mr. McBrayer has led various orthopedic and regenerative medicine companies and has been an advisor to medical device companies in the spine, orthopedics and biotechnology spaces. Before joining Miach Orthopaedics, he served as president and CEO of ACell, AxioMed Spine Corp., Exogen and Osteotech; CEO of Xylos Corporation; and co-founder of Transave (now Insmed).
Mr. McBrayer will be responsible for leading Miach Orthopaedics, an early-stage company that recently launched the Bear implant commercially in the U.S. The Bear implant is designed to bridge the ACL and allow the patient's blood to repair the ligament.
"The team at Miach Orthopaedics has made tremendous progress over the last year in driving market adoption of the BEAR Implant for ACL restoration," Mr. McBrayer said in the release. "Surgeons and patients alike understand the benefits of healing a torn ACL rather than replacing it, and I look forward to leading Miach as we work to establish the Bear implant as the new standard of care for ACL tear surgery."
Mr. McBrayer replaces Christopher Joyce, who served as interim president and CEO since Martha Shadan left the company in June. Mr. Joyce will return to his previous role as CFO.